Cargando…

How Can We Engineer CAR T Cells to Overcome Resistance?

Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as suc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glover, Maya, Avraamides, Stephanie, Maher, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141613/ https://www.ncbi.nlm.nih.gov/pubmed/34040345 http://dx.doi.org/10.2147/BTT.S252568

Ejemplares similares

How can Cytokine-induced killer cells overcome CAR-T cell limits
por: Cappuzzello, Elisa, et al.
Publicado: (2023)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

How can we overcome health inequalities in psychiatry?
por: Monk-Cunliffe, Jonathan
Publicado: (2023)

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
por: Li, Li, et al.
Publicado: (2023)

CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
por: Vanhooren, Jolien, et al.
Publicado: (2023)

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
por: Andrea, Alain E., et al.
Publicado: (2022)

Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
por: Song, Moo-Kon, et al.
Publicado: (2019)

Donor shortage in heart transplantation: How can we overcome this challenge?
por: Cameli, Matteo, et al.
Publicado: (2022)

Improving anticoagulation in sub‐Saharan Africa: What are the challenges and how can we overcome them?
por: Mouton, Johannes P., et al.
Publicado: (2021)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

New antibiotic agents in the pipeline and how they can help overcome microbial resistance
por: Gould, Ian M., et al.
Publicado: (2013)

Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Skin Barriers in Dermal Drug Delivery: Which Barriers Have to Be Overcome and How Can We Measure Them?
por: Gorzelanny, Christian, et al.
Publicado: (2020)

Overcoming Shellfish Allergy: How Far Have We Come? †
por: Wai, Christine Y.Y., et al.
Publicado: (2020)

Anthelmintics Resistance; How to Overcome it?
por: Shalaby, Hatem A.
Publicado: (2013)

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome
por: Kim, Jae-Young, et al.
Publicado: (2017)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

How Can We Overcome the Strength–Ductility Tradeoff in Light Alloys and Related Composites?
por: Gao, Tong, et al.
Publicado: (2023)

Vector-borne parasites: Can we overcome it?
por: Parija, Subhash Chandra
Publicado: (2018)

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
por: Kailayangiri, Sareetha, et al.
Publicado: (2020)

CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
por: Luksik, Andrew S., et al.
Publicado: (2023)

Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Publicado: (2021)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Born to survive: how cancer cells resist CAR T cell therapy
por: Lemoine, Jean, et al.
Publicado: (2021)

How CAR T Cells Breathe
por: Forcados, Christopher, et al.
Publicado: (2022)

Why is Misdiagnosis of von Willebrand Disease Still Prevalent and How Can We Overcome It? A Focus on Clinical Considerations and Recommendations
por: Colonne, Chanukya K, et al.
Publicado: (2021)

Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?
por: Prihantono, et al.
Publicado: (2021)

Recent advances in CAR-T cell engineering
por: Huang, Ruihao, et al.
Publicado: (2020)

Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?
por: McDonald, Kerrie L., et al.
Publicado: (2013)

Engineering Next-Generation CAR-T Cells for Better Toxicity Management
por: Andrea, Alain E., et al.
Publicado: (2020)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
por: Haronikova, Lucia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_49q6po6mo6jdubl3oof26e9j7s